Panion at European Innovation Day
The European Medicines Agency (EMA) is the regulatory body that authorises biotechnological veterinary medicines in Europe. Thursday the 19.th of April 2018, the Agency held a well-visited day for businesses that work with innovative projects to keep them abreast with the current developments in authorisation requirements; the EMA veterinary medicines innovation day.
Panion’s CEO, Anja Holm, participated to ensure that the most recent decisions and practises are available for Panion’s development programme and to meet representatives from the authorities and from other companies with products in the development phase. The program comprised speakers from the European Commission, EMA, the veterinary scientific committee and veterinary medicine inventors.
Updates were presented on the financial and regulatory incentives for Small and Mediumsized Enterprises (SME), on Minor Use Minor Species (MUMS) policies, on the advantages of Innovation Task Force meetings, and on scientific advices from EMA.
“This has been a very informative and useful day from Panion’s perspective, and we have several ideas to pursue” says Anja Holm.
Anja E. H. Holm, CEO
+ 45-22 94 66 00
Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.